Log In
Print
BCIQ
Print
Print this Print this
 

Iclusig, ponatinib (formerly AP24534)

Also known as: 534

  Manage Alerts
Collapse Summary General Information
Company Ariad Pharmaceuticals Inc.
DescriptionPan-BCR-ABL tyrosine kinase inhibitor (TKI)
Molecular Target BCR-ABL tyrosine kinase ; FMS-like tyrosine kinase 3 (FLT3) (CD135)
Mechanism of Action 
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today